AU2007212126B2 - Compounds and methods for modulating FX-receptors - Google Patents
Compounds and methods for modulating FX-receptors Download PDFInfo
- Publication number
- AU2007212126B2 AU2007212126B2 AU2007212126A AU2007212126A AU2007212126B2 AU 2007212126 B2 AU2007212126 B2 AU 2007212126B2 AU 2007212126 A AU2007212126 A AU 2007212126A AU 2007212126 A AU2007212126 A AU 2007212126A AU 2007212126 B2 AU2007212126 B2 AU 2007212126B2
- Authority
- AU
- Australia
- Prior art keywords
- phenyl
- methyl
- carboxylic acid
- isoxazol
- isopropyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 230
- 238000000034 method Methods 0.000 title claims abstract description 27
- 208000032928 Dyslipidaemia Diseases 0.000 claims abstract description 18
- 208000017170 Lipid metabolism disease Diseases 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims description 114
- -1 benzoisoxazolyl Chemical group 0.000 claims description 43
- 229910052739 hydrogen Inorganic materials 0.000 claims description 36
- 239000001257 hydrogen Substances 0.000 claims description 33
- 125000000217 alkyl group Chemical group 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 19
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 17
- 150000002431 hydrogen Chemical class 0.000 claims description 16
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 14
- 125000005843 halogen group Chemical group 0.000 claims description 13
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 13
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 12
- 125000003944 tolyl group Chemical group 0.000 claims description 11
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 125000001153 fluoro group Chemical group F* 0.000 claims description 9
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 8
- 125000001041 indolyl group Chemical group 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- 125000001544 thienyl group Chemical group 0.000 claims description 8
- 201000001320 Atherosclerosis Diseases 0.000 claims description 7
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 7
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 125000005119 alkyl cycloalkyl group Chemical group 0.000 claims description 4
- ZVTQYRVARPYRRE-UHFFFAOYSA-N oxadiazol-4-one Chemical compound O=C1CON=N1 ZVTQYRVARPYRRE-UHFFFAOYSA-N 0.000 claims description 4
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 3
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 3
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 2
- JNGDFYLGDPAEBY-UHFFFAOYSA-N oxadiazole-4-thione Chemical compound S=C1CON=N1 JNGDFYLGDPAEBY-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- XWMXMWHHTIEXRE-UHFFFAOYSA-N thiadiazole 1-oxide Chemical compound O=S1C=CN=N1 XWMXMWHHTIEXRE-UHFFFAOYSA-N 0.000 claims description 2
- XWDMAGXYQPWSDN-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-1-benzothiophene-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3SC=C(C3=CC=2)C(O)=O)C(C)=CC=1OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F XWDMAGXYQPWSDN-UHFFFAOYSA-N 0.000 claims 3
- QJFJBHYIIFGMSF-UHFFFAOYSA-N 6-[2-methyl-4-[[5-propan-2-yl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]phenyl]-1-benzothiophene-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3SC=C(C3=CC=2)C(O)=O)C(C)=CC=1OCC1=C(C(C)C)ON=C1C1=CC=CC=C1OC(F)(F)F QJFJBHYIIFGMSF-UHFFFAOYSA-N 0.000 claims 2
- KZSBGQYBMRPUGK-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]phenyl]-1-propan-2-ylindole-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3N(C(C)C)C=C(C3=CC=2)C(O)=O)C=CC=1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl KZSBGQYBMRPUGK-UHFFFAOYSA-N 0.000 claims 2
- WRYFJPMYDZTZDM-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]phenyl]-1,2-benzothiazole-3-carboxylic acid Chemical compound C=1C=C2C(C(=O)O)=NSC2=CC=1C(C=C1)=CC=C1OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F WRYFJPMYDZTZDM-UHFFFAOYSA-N 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- UDHVEBAZALTEPC-UHFFFAOYSA-N 2-[2-methyl-4-[[5-propan-2-yl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]phenyl]-1,3-thiazole-5-carboxylic acid Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2)OC(F)(F)F)C=1COC(C=C1C)=CC=C1C1=NC=C(C(O)=O)S1 UDHVEBAZALTEPC-UHFFFAOYSA-N 0.000 claims 1
- WTVHUEAULKJHLB-UHFFFAOYSA-N 2-[4-[[5-cyclopropyl-3-[2-fluoro-6-(trifluoromethyl)phenyl]-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-4-methyl-1,3-thiazole-5-carboxylic acid Chemical compound S1C(C(O)=O)=C(C)N=C1C(C(=C1)C)=CC=C1OCC1=C(C2CC2)ON=C1C1=C(F)C=CC=C1C(F)(F)F WTVHUEAULKJHLB-UHFFFAOYSA-N 0.000 claims 1
- SSOKAWOHMOSIJQ-UHFFFAOYSA-N 4-methyl-2-[2-methyl-4-[[5-propan-2-yl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]phenyl]-1,3-thiazole-5-carboxylic acid Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2)OC(F)(F)F)C=1COC(C=C1C)=CC=C1C1=NC(C)=C(C(O)=O)S1 SSOKAWOHMOSIJQ-UHFFFAOYSA-N 0.000 claims 1
- VXJUTMUZMNGPBO-UHFFFAOYSA-N 5-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-4-methylthiophene-2-carboxylic acid Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2Cl)Cl)C=1COC(C=C1C)=CC=C1C=1SC(C(O)=O)=CC=1C VXJUTMUZMNGPBO-UHFFFAOYSA-N 0.000 claims 1
- QWJGNTHOQWQFFL-UHFFFAOYSA-N 5-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-4-methylthiophene-2-carboxylic acid Chemical compound C1=C(C(O)=O)SC(C=2C(=CC(OCC=3C(=NOC=3C3CC3)C=3C(=CC=CC=3Cl)Cl)=CC=2)C)=C1C QWJGNTHOQWQFFL-UHFFFAOYSA-N 0.000 claims 1
- CDHJFALRGJMKIE-UHFFFAOYSA-N 5-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]thiophene-2-carboxylic acid Chemical compound C=1C=C(C=2SC(=CC=2)C(O)=O)C(C)=CC=1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl CDHJFALRGJMKIE-UHFFFAOYSA-N 0.000 claims 1
- DJIPMJOPIWKCLD-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-1-benzothiophene-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3SC=C(C3=CC=2)C(O)=O)C(C)=CC=1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl DJIPMJOPIWKCLD-UHFFFAOYSA-N 0.000 claims 1
- CBZGTSZJINLFEQ-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-1-methylindole-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3N(C)C=C(C3=CC=2)C(O)=O)C(C)=CC=1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl CBZGTSZJINLFEQ-UHFFFAOYSA-N 0.000 claims 1
- OOOHZAYEJFWVSE-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-2-methyl-1-benzofuran-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3OC(C)=C(C(O)=O)C3=CC=2)C(C)=CC=1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl OOOHZAYEJFWVSE-UHFFFAOYSA-N 0.000 claims 1
- BYKHFMZYLWYZSF-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-2-methyl-1-propan-2-ylindole-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3N(C(C)C)C(C)=C(C(O)=O)C3=CC=2)C(C)=CC=1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl BYKHFMZYLWYZSF-UHFFFAOYSA-N 0.000 claims 1
- PVQOIMYKUJFHSV-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]phenyl]-1,2-benzothiazole-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3SN=C(C3=CC=2)C(O)=O)C=CC=1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl PVQOIMYKUJFHSV-UHFFFAOYSA-N 0.000 claims 1
- ZZIKYOSVNOPNQR-UHFFFAOYSA-N 6-[4-[[3-(2,6-dichlorophenyl)-5-propan-2-yl-1,2-oxazol-4-yl]methoxy]phenyl]-1-propan-2-ylindazole-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3N(C(C)C)N=C(C3=CC=2)C(O)=O)C=CC=1OCC1=C(C(C)C)ON=C1C1=C(Cl)C=CC=C1Cl ZZIKYOSVNOPNQR-UHFFFAOYSA-N 0.000 claims 1
- XAAWGJUGXCHHTM-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-1,2-benzoxazole-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3ON=C(C3=CC=2)C(O)=O)C(C)=CC=1OCC=1C(C=2C(=CC=CC=2Cl)Cl)=NOC=1C1CC1 XAAWGJUGXCHHTM-UHFFFAOYSA-N 0.000 claims 1
- UUYQPCIBFJNDPY-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-1-benzothiophene-3-carboxylic acid Chemical compound C=1C=C(C=2C=C3SC=C(C3=CC=2)C(O)=O)C(C)=CC=1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl UUYQPCIBFJNDPY-UHFFFAOYSA-N 0.000 claims 1
- XIKIQAPAEXOOSR-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]phenyl]-1,2-benzothiazole-3-carboxylic acid Chemical compound C=1C=C2C(C(=O)O)=NSC2=CC=1C(C=C1)=CC=C1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl XIKIQAPAEXOOSR-UHFFFAOYSA-N 0.000 claims 1
- YDYNTEWMHLSXMZ-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-1-propan-2-ylindole-3-carboxylic acid Chemical compound C1=C2N(C(C)C)C=C(C(O)=O)C2=CC=C1C(C(=C1)C)=CC=C1OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F YDYNTEWMHLSXMZ-UHFFFAOYSA-N 0.000 claims 1
- UICHUVJHVIHQHD-UHFFFAOYSA-N 6-[4-[[5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]-2-methyl-1-benzothiophene-3-carboxylic acid Chemical compound C=1C=C2C(C(O)=O)=C(C)SC2=CC=1C(C(=C1)C)=CC=C1OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F UICHUVJHVIHQHD-UHFFFAOYSA-N 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 293
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 173
- 239000000203 mixture Substances 0.000 description 152
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 143
- 239000000243 solution Substances 0.000 description 129
- 235000019439 ethyl acetate Nutrition 0.000 description 122
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 109
- 230000002829 reductive effect Effects 0.000 description 96
- 239000002253 acid Substances 0.000 description 85
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 83
- 239000011541 reaction mixture Substances 0.000 description 74
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 55
- 238000006243 chemical reaction Methods 0.000 description 55
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 49
- 239000012044 organic layer Substances 0.000 description 49
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 48
- 239000007787 solid Substances 0.000 description 47
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 44
- 238000005481 NMR spectroscopy Methods 0.000 description 44
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 43
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 36
- 239000010410 layer Substances 0.000 description 36
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 34
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 29
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 239000012267 brine Substances 0.000 description 26
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 26
- 238000003818 flash chromatography Methods 0.000 description 25
- 150000004702 methyl esters Chemical class 0.000 description 25
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 24
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 21
- 239000012043 crude product Substances 0.000 description 20
- 238000010898 silica gel chromatography Methods 0.000 description 20
- 239000011734 sodium Substances 0.000 description 20
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 18
- 239000000706 filtrate Substances 0.000 description 18
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- 239000002904 solvent Substances 0.000 description 16
- 238000003756 stirring Methods 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- 102100038495 Bile acid receptor Human genes 0.000 description 15
- 101000603876 Homo sapiens Bile acid receptor Proteins 0.000 description 15
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 15
- 239000003921 oil Substances 0.000 description 15
- 125000004494 ethyl ester group Chemical group 0.000 description 14
- SKZJYJMYLUQJPG-UHFFFAOYSA-N methyl 6-bromo-1h-indole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OC)=CNC2=C1 SKZJYJMYLUQJPG-UHFFFAOYSA-N 0.000 description 14
- 238000010992 reflux Methods 0.000 description 14
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 13
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 12
- 229910000027 potassium carbonate Inorganic materials 0.000 description 12
- 229910052938 sodium sulfate Inorganic materials 0.000 description 12
- 235000011152 sodium sulphate Nutrition 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 10
- 238000004587 chromatography analysis Methods 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 10
- 239000000741 silica gel Substances 0.000 description 10
- 229910002027 silica gel Inorganic materials 0.000 description 10
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 10
- 239000005909 Kieselgur Substances 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 235000012000 cholesterol Nutrition 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 125000004188 dichlorophenyl group Chemical group 0.000 description 8
- 238000001914 filtration Methods 0.000 description 8
- 150000002632 lipids Chemical class 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000019341 magnesium sulphate Nutrition 0.000 description 8
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 7
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 7
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 7
- 125000005605 benzo group Chemical group 0.000 description 7
- 238000004440 column chromatography Methods 0.000 description 7
- 239000012065 filter cake Substances 0.000 description 7
- KMAKOBLIOCQGJP-UHFFFAOYSA-N indole-3carboxylic acid Natural products C1=CC=C2C(C(=O)O)=CNC2=C1 KMAKOBLIOCQGJP-UHFFFAOYSA-N 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 239000012312 sodium hydride Substances 0.000 description 7
- 229910000104 sodium hydride Inorganic materials 0.000 description 7
- 239000007858 starting material Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 125000000753 cycloalkyl group Chemical group 0.000 description 6
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- 229940124530 sulfonamide Drugs 0.000 description 6
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 6
- WLPUWLXVBWGYMZ-UHFFFAOYSA-N tricyclohexylphosphine Chemical compound C1CCCCC1P(C1CCCCC1)C1CCCCC1 WLPUWLXVBWGYMZ-UHFFFAOYSA-N 0.000 description 6
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- AMSQNQJCBXQYEX-UHFFFAOYSA-N (4-methoxy-2-methylphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C(C)=C1 AMSQNQJCBXQYEX-UHFFFAOYSA-N 0.000 description 5
- 101150041968 CDC13 gene Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 5
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- MFOKOKHNSVUKON-UHFFFAOYSA-N methyl 5-bromo-1H-indole-3-carboxylate Natural products C1=C(Br)C=C2C(C(=O)OC)=CNC2=C1 MFOKOKHNSVUKON-UHFFFAOYSA-N 0.000 description 5
- QXAUTQFAWKKNLM-UHFFFAOYSA-N methyl indole-3-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CNC2=C1 QXAUTQFAWKKNLM-UHFFFAOYSA-N 0.000 description 5
- 239000002480 mineral oil Substances 0.000 description 5
- 235000010446 mineral oil Nutrition 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- TUQOTMZNTHZOKS-UHFFFAOYSA-N tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 5
- DYSJMQABFPKAQM-UHFFFAOYSA-N 1-benzothiophene-2-carboxylic acid Chemical compound C1=CC=C2SC(C(=O)O)=CC2=C1 DYSJMQABFPKAQM-UHFFFAOYSA-N 0.000 description 4
- 238000010485 C−C bond formation reaction Methods 0.000 description 4
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 4
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 4
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 4
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- OKJPEAGHQZHRQV-UHFFFAOYSA-N Triiodomethane Natural products IC(I)I OKJPEAGHQZHRQV-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- XJHCXCQVJFPJIK-UHFFFAOYSA-M caesium fluoride Chemical compound [F-].[Cs+] XJHCXCQVJFPJIK-UHFFFAOYSA-M 0.000 description 4
- RLMWPNDSVWJWHA-UHFFFAOYSA-N methyl 6-bromo-1-methylindole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OC)=CN(C)C2=C1 RLMWPNDSVWJWHA-UHFFFAOYSA-N 0.000 description 4
- KXKVLQRXCPHEJC-UHFFFAOYSA-N methyl acetate Chemical compound COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 4
- 229920006395 saturated elastomer Polymers 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 4
- 150000003626 triacylglycerols Chemical class 0.000 description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 238000010792 warming Methods 0.000 description 4
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 3
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- PJNILWKRAKKEQM-UHFFFAOYSA-N 2-bromo-6-fluorobenzaldehyde Chemical compound FC1=CC=CC(Br)=C1C=O PJNILWKRAKKEQM-UHFFFAOYSA-N 0.000 description 3
- GPOQODYGMUTOQL-UHFFFAOYSA-N 4-bromo-3-methylphenol Chemical compound CC1=CC(O)=CC=C1Br GPOQODYGMUTOQL-UHFFFAOYSA-N 0.000 description 3
- OQIMJOXSDVGEBU-UHFFFAOYSA-N 6-bromo-1-benzothiophene Chemical compound BrC1=CC=C2C=CSC2=C1 OQIMJOXSDVGEBU-UHFFFAOYSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 3
- 125000003545 alkoxy group Chemical group 0.000 description 3
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 150000001721 carbon Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- PDXUKFQPTWVRTN-UHFFFAOYSA-N ethyl 6-(trifluoromethylsulfonyloxy)-1-benzofuran-3-carboxylate Chemical compound FC(F)(F)S(=O)(=O)OC1=CC=C2C(C(=O)OCC)=COC2=C1 PDXUKFQPTWVRTN-UHFFFAOYSA-N 0.000 description 3
- 125000004498 isoxazol-4-yl group Chemical group O1N=CC(=C1)* 0.000 description 3
- 150000002545 isoxazoles Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- BUMYRKNZGPXFEG-UHFFFAOYSA-N methyl 6-bromo-1h-indole-2-carboxylate Chemical compound C1=C(Br)C=C2NC(C(=O)OC)=CC2=C1 BUMYRKNZGPXFEG-UHFFFAOYSA-N 0.000 description 3
- RPUAGJVFXJADEK-UHFFFAOYSA-N methyl 6-chloro-2-methyl-1h-indole-3-carboxylate Chemical compound ClC1=CC=C2C(C(=O)OC)=C(C)NC2=C1 RPUAGJVFXJADEK-UHFFFAOYSA-N 0.000 description 3
- 229910052763 palladium Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
- 239000011343 solid material Substances 0.000 description 3
- 150000003456 sulfonamides Chemical class 0.000 description 3
- OWMYOPDVDDBVAA-UHFFFAOYSA-N tert-butyl 6-(trifluoromethylsulfonyloxy)-1-benzofuran-2-carboxylate Chemical compound C1=C(OS(=O)(=O)C(F)(F)F)C=C2OC(C(=O)OC(C)(C)C)=CC2=C1 OWMYOPDVDDBVAA-UHFFFAOYSA-N 0.000 description 3
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 3
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 2
- BENJFDPHDCGUAQ-UHFFFAOYSA-N 1-benzofuran-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=COC2=C1 BENJFDPHDCGUAQ-UHFFFAOYSA-N 0.000 description 2
- REVHWEJAHDLSTJ-UHFFFAOYSA-N 1-benzothiophene-4-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=C1C=CS2 REVHWEJAHDLSTJ-UHFFFAOYSA-N 0.000 description 2
- LJPSRTWIAXVPIS-UHFFFAOYSA-N 1-benzothiophene-7-carboxylic acid Chemical compound OC(=O)C1=CC=CC2=C1SC=C2 LJPSRTWIAXVPIS-UHFFFAOYSA-N 0.000 description 2
- IUNJCFABHJZSKB-UHFFFAOYSA-N 2,4-dihydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C(O)=C1 IUNJCFABHJZSKB-UHFFFAOYSA-N 0.000 description 2
- VMUFNTKYYQNRKK-UHFFFAOYSA-N 2-borono-1-benzothiophene-4-carboxylic acid Chemical compound C1=CC=C2SC(B(O)O)=CC2=C1C(O)=O VMUFNTKYYQNRKK-UHFFFAOYSA-N 0.000 description 2
- NAMYKGVDVNBCFQ-UHFFFAOYSA-N 2-bromopropane Chemical compound CC(C)Br NAMYKGVDVNBCFQ-UHFFFAOYSA-N 0.000 description 2
- AMLKEDBYDOCGEG-UHFFFAOYSA-N 2-hydroxy-4-phenylmethoxybenzaldehyde Chemical compound C1=C(C=O)C(O)=CC(OCC=2C=CC=CC=2)=C1 AMLKEDBYDOCGEG-UHFFFAOYSA-N 0.000 description 2
- BKOOMYPCSUNDGP-UHFFFAOYSA-N 2-methylbut-2-ene Chemical compound CC=C(C)C BKOOMYPCSUNDGP-UHFFFAOYSA-N 0.000 description 2
- KQELZLCLCNPDMC-UHFFFAOYSA-N 3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenol Chemical compound CC1=CC(O)=CC=C1B1OC(C)(C)C(C)(C)O1 KQELZLCLCNPDMC-UHFFFAOYSA-N 0.000 description 2
- QPBSEYFVZDMBFW-UHFFFAOYSA-N 4-bromo-1-benzothiophene Chemical compound BrC1=CC=CC2=C1C=CS2 QPBSEYFVZDMBFW-UHFFFAOYSA-N 0.000 description 2
- UWDMKTDPDJCJOP-UHFFFAOYSA-N 4-hydroxy-2,2,6,6-tetramethylpiperidin-1-ium-4-carboxylate Chemical compound CC1(C)CC(O)(C(O)=O)CC(C)(C)N1 UWDMKTDPDJCJOP-UHFFFAOYSA-N 0.000 description 2
- AWYWWZGPZAZBEQ-UHFFFAOYSA-N 4-methyl-5-[2-methyl-4-[[5-propan-2-yl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methoxy]phenyl]thiophene-2-carbohydrazide Chemical compound CC(C)C=1ON=C(C=2C(=CC=CC=2)OC(F)(F)F)C=1COC(C=C1C)=CC=C1C=1SC(C(=O)NN)=CC=1C AWYWWZGPZAZBEQ-UHFFFAOYSA-N 0.000 description 2
- JVZMBSGNSAHFCY-UHFFFAOYSA-N 5-bromo-1h-indole-3-carboxylic acid Chemical compound C1=C(Br)C=C2C(C(=O)O)=CNC2=C1 JVZMBSGNSAHFCY-UHFFFAOYSA-N 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 2
- CKBBSFOOIOHLPC-UHFFFAOYSA-N 6-bromo-1-benzothiophene-2-carboxylic acid Chemical compound C1=C(Br)C=C2SC(C(=O)O)=CC2=C1 CKBBSFOOIOHLPC-UHFFFAOYSA-N 0.000 description 2
- SVBVYRYROZWKNJ-UHFFFAOYSA-N 6-bromo-1h-indole-2-carboxylic acid Chemical compound C1=C(Br)C=C2NC(C(=O)O)=CC2=C1 SVBVYRYROZWKNJ-UHFFFAOYSA-N 0.000 description 2
- INNZWYJJSSRJET-UHFFFAOYSA-N 6-bromo-1h-indole-3-carboxylic acid Chemical compound BrC1=CC=C2C(C(=O)O)=CNC2=C1 INNZWYJJSSRJET-UHFFFAOYSA-N 0.000 description 2
- AHAVOXPDABUPJT-UHFFFAOYSA-N 6-methoxy-2-methyl-1-benzofuran Chemical compound COC1=CC=C2C=C(C)OC2=C1 AHAVOXPDABUPJT-UHFFFAOYSA-N 0.000 description 2
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 229910021595 Copper(I) iodide Inorganic materials 0.000 description 2
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical compound C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 229910004298 SiO 2 Inorganic materials 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- AVRWEULSKHQETA-UHFFFAOYSA-N Thiophene-2 Chemical compound S1C=2CCCCCC=2C(C(=O)OC)=C1NC(=O)C1=C(F)C(F)=C(F)C(F)=C1F AVRWEULSKHQETA-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 description 2
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 2
- IPWKHHSGDUIRAH-UHFFFAOYSA-N bis(pinacolato)diboron Chemical compound O1C(C)(C)C(C)(C)OB1B1OC(C)(C)C(C)(C)O1 IPWKHHSGDUIRAH-UHFFFAOYSA-N 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- LSXDOTMGLUJQCM-UHFFFAOYSA-M copper(i) iodide Chemical compound I[Cu] LSXDOTMGLUJQCM-UHFFFAOYSA-M 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 2
- GGFKOVMZDAWYEX-UHFFFAOYSA-N dicyclohexyl-(1,3-dimethoxy-2-phenylcyclohexa-2,4-dien-1-yl)phosphane Chemical group C1CCCCC1P(C1CCCCC1)C1(OC)CC=CC(OC)=C1C1=CC=CC=C1 GGFKOVMZDAWYEX-UHFFFAOYSA-N 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- HHFXANRCFLCNJW-UHFFFAOYSA-N ethyl 2-(4-methoxy-2-methylphenyl)-1-benzothiophene-5-carboxylate Chemical compound C=1C2=CC(C(=O)OCC)=CC=C2SC=1C1=CC=C(OC)C=C1C HHFXANRCFLCNJW-UHFFFAOYSA-N 0.000 description 2
- SAYUBFVIKXSBTI-UHFFFAOYSA-N ethyl 2-amino-4-propan-2-yl-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(C)C SAYUBFVIKXSBTI-UHFFFAOYSA-N 0.000 description 2
- FCZCIXQGZOUIDN-UHFFFAOYSA-N ethyl 2-diethoxyphosphinothioyloxyacetate Chemical compound CCOC(=O)COP(=S)(OCC)OCC FCZCIXQGZOUIDN-UHFFFAOYSA-N 0.000 description 2
- KYZJZLYWFGSJSD-UHFFFAOYSA-N ethyl 3-(cyclopropylamino)but-2-enoate Chemical compound CCOC(=O)C=C(C)NC1CC1 KYZJZLYWFGSJSD-UHFFFAOYSA-N 0.000 description 2
- CSLCYFFJPLEVAX-UHFFFAOYSA-N ethyl 6-methoxy-1-benzofuran-3-carboxylate Chemical compound COC1=CC=C2C(C(=O)OCC)=COC2=C1 CSLCYFFJPLEVAX-UHFFFAOYSA-N 0.000 description 2
- 229940121360 farnesoid X receptor (fxr) agonists Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 125000004438 haloalkoxy group Chemical group 0.000 description 2
- 125000001188 haloalkyl group Chemical group 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- PUYCICVJCRLABY-UHFFFAOYSA-N heptane;oxolane Chemical compound C1CCOC1.CCCCCCC PUYCICVJCRLABY-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- OWFXIOWLTKNBAP-UHFFFAOYSA-N isoamyl nitrite Chemical compound CC(C)CCON=O OWFXIOWLTKNBAP-UHFFFAOYSA-N 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- HNQIVZYLYMDVSB-UHFFFAOYSA-N methanesulfonimidic acid Chemical compound CS(N)(=O)=O HNQIVZYLYMDVSB-UHFFFAOYSA-N 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- KRRAZMUPVIGDCU-UHFFFAOYSA-N methyl 1-benzothiophene-2-carboxylate Chemical compound C1=CC=C2SC(C(=O)OC)=CC2=C1 KRRAZMUPVIGDCU-UHFFFAOYSA-N 0.000 description 2
- FSJAXBXCHWMNAB-UHFFFAOYSA-N methyl 1-benzothiophene-3-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=CSC2=C1 FSJAXBXCHWMNAB-UHFFFAOYSA-N 0.000 description 2
- FIRYVFXZPZNHBP-UHFFFAOYSA-N methyl 2-[1-methyl-6-(trifluoromethylsulfonyloxy)indol-3-yl]acetate Chemical compound FC(F)(F)S(=O)(=O)OC1=CC=C2C(CC(=O)OC)=CN(C)C2=C1 FIRYVFXZPZNHBP-UHFFFAOYSA-N 0.000 description 2
- IHXXYBKSTSUCGT-UHFFFAOYSA-N methyl 2-methyl-6-(trifluoromethylsulfonyloxy)-1-benzofuran-3-carboxylate Chemical compound FC(F)(F)S(=O)(=O)OC1=CC=C2C(C(=O)OC)=C(C)OC2=C1 IHXXYBKSTSUCGT-UHFFFAOYSA-N 0.000 description 2
- MIZNLOQJTYKTDH-UHFFFAOYSA-N methyl 2-oxo-2-(6-phenylmethoxy-1h-indol-3-yl)acetate Chemical compound C=1C=C2C(C(=O)C(=O)OC)=CNC2=CC=1OCC1=CC=CC=C1 MIZNLOQJTYKTDH-UHFFFAOYSA-N 0.000 description 2
- RJWZFHRMQRWEIH-UHFFFAOYSA-N methyl 5-bromo-4-methylthiophene-2-carboxylate Chemical compound COC(=O)C1=CC(C)=C(Br)S1 RJWZFHRMQRWEIH-UHFFFAOYSA-N 0.000 description 2
- DARFSEJSQSSMAL-UHFFFAOYSA-N methyl 6-bromo-1-(2-methoxyethyl)indole-3-carboxylate Chemical compound C1=C(Br)C=C2N(CCOC)C=C(C(=O)OC)C2=C1 DARFSEJSQSSMAL-UHFFFAOYSA-N 0.000 description 2
- RVKHRBDHVYZAGL-UHFFFAOYSA-N methyl 6-bromo-1-[2-(dimethylamino)ethyl]indole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OC)=CN(CCN(C)C)C2=C1 RVKHRBDHVYZAGL-UHFFFAOYSA-N 0.000 description 2
- SFDVDNLBYGHFNF-UHFFFAOYSA-N methyl 6-bromo-1-benzothiophene-2-carboxylate Chemical compound C1=C(Br)C=C2SC(C(=O)OC)=CC2=C1 SFDVDNLBYGHFNF-UHFFFAOYSA-N 0.000 description 2
- SJICLOHNXORMBV-UHFFFAOYSA-N methyl 6-bromo-1-methylindazole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OC)=NN(C)C2=C1 SJICLOHNXORMBV-UHFFFAOYSA-N 0.000 description 2
- FIPMZRPZSZXFGK-UHFFFAOYSA-N methyl 6-bromo-1h-indazole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OC)=NNC2=C1 FIPMZRPZSZXFGK-UHFFFAOYSA-N 0.000 description 2
- YNBADRVTZLEFNH-UHFFFAOYSA-N methyl nicotinate Chemical compound COC(=O)C1=CC=CN=C1 YNBADRVTZLEFNH-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- LQNUZADURLCDLV-UHFFFAOYSA-N nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1 LQNUZADURLCDLV-UHFFFAOYSA-N 0.000 description 2
- 239000012299 nitrogen atmosphere Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 2
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- DROIHSMGGKKIJT-UHFFFAOYSA-N propane-1-sulfonamide Chemical compound CCCS(N)(=O)=O DROIHSMGGKKIJT-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 230000004224 protection Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000007115 recruitment Effects 0.000 description 2
- 238000002390 rotary evaporation Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000012258 stirred mixture Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000011269 tar Substances 0.000 description 2
- JMEOCQVBRYEHJF-UHFFFAOYSA-N tert-butyl 6-hydroxy-1-benzofuran-2-carboxylate Chemical compound C1=C(O)C=C2OC(C(=O)OC(C)(C)C)=CC2=C1 JMEOCQVBRYEHJF-UHFFFAOYSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- HJUGFYREWKUQJT-UHFFFAOYSA-N tetrabromomethane Chemical compound BrC(Br)(Br)Br HJUGFYREWKUQJT-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 229910052727 yttrium Inorganic materials 0.000 description 2
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
- JSMBJYBJBSYGIN-UHFFFAOYSA-N (2-methyl-1-benzofuran-6-yl) acetate Chemical compound CC(=O)OC1=CC=C2C=C(C)OC2=C1 JSMBJYBJBSYGIN-UHFFFAOYSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 1
- VOAAEKKFGLPLLU-UHFFFAOYSA-N (4-methoxyphenyl)boronic acid Chemical compound COC1=CC=C(B(O)O)C=C1 VOAAEKKFGLPLLU-UHFFFAOYSA-N 0.000 description 1
- YGEBIGMLMWYGHE-UHFFFAOYSA-N (6-bromo-1-benzothiophen-2-yl)methanol Chemical compound C1=C(Br)C=C2SC(CO)=CC2=C1 YGEBIGMLMWYGHE-UHFFFAOYSA-N 0.000 description 1
- QYBDTSQIDAOQSS-UHFFFAOYSA-N (6-methoxy-1-benzofuran-3-yl) trifluoromethanesulfonate Chemical compound COC1=CC=C2C(OS(=O)(=O)C(F)(F)F)=COC2=C1 QYBDTSQIDAOQSS-UHFFFAOYSA-N 0.000 description 1
- OQJBFFCUFALWQL-BUHFOSPRSA-N (ne)-n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)\N=N\C(=O)N1CCCCC1 OQJBFFCUFALWQL-BUHFOSPRSA-N 0.000 description 1
- KYVBNYUBXIEUFW-UHFFFAOYSA-N 1,1,3,3-tetramethylguanidine Chemical compound CN(C)C(=N)N(C)C KYVBNYUBXIEUFW-UHFFFAOYSA-N 0.000 description 1
- LVEYOSJUKRVCCF-UHFFFAOYSA-N 1,3-bis(diphenylphosphino)propane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCP(C=1C=CC=CC=1)C1=CC=CC=C1 LVEYOSJUKRVCCF-UHFFFAOYSA-N 0.000 description 1
- SNBYTKLWZRHESA-UHFFFAOYSA-N 1-benzothiophene-5-carboxylic acid Chemical compound OC(=O)C1=CC=C2SC=CC2=C1 SNBYTKLWZRHESA-UHFFFAOYSA-N 0.000 description 1
- VMGLLMDIYIPVHX-UHFFFAOYSA-N 1-benzothiophene-6-carboxylic acid Chemical compound OC(=O)C1=CC=C2C=CSC2=C1 VMGLLMDIYIPVHX-UHFFFAOYSA-N 0.000 description 1
- QDFKKJYEIFBEFC-UHFFFAOYSA-N 1-bromo-3-fluorobenzene Chemical compound FC1=CC=CC(Br)=C1 QDFKKJYEIFBEFC-UHFFFAOYSA-N 0.000 description 1
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 1
- AWDVBWLFMYVPAZ-UHFFFAOYSA-N 1H-indole-3-carboxylic acid methyl 1-propan-2-ylindole-3-carboxylate Chemical compound COC(=O)C1=CN(C2=CC=CC=C12)C(C)C.N1C=C(C2=CC=CC=C12)C(=O)O AWDVBWLFMYVPAZ-UHFFFAOYSA-N 0.000 description 1
- BHXVYTQDWMQVBI-UHFFFAOYSA-N 1h-indazole-3-carboxylic acid Chemical compound C1=CC=C2C(C(=O)O)=NNC2=C1 BHXVYTQDWMQVBI-UHFFFAOYSA-N 0.000 description 1
- DMIYKWPEFRFTPY-UHFFFAOYSA-N 2,6-dichlorobenzaldehyde Chemical compound ClC1=CC=CC(Cl)=C1C=O DMIYKWPEFRFTPY-UHFFFAOYSA-N 0.000 description 1
- LBZPHZBNFDOCCR-UHFFFAOYSA-N 2-(4-bromo-2-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(Br)C=C1[N+]([O-])=O LBZPHZBNFDOCCR-UHFFFAOYSA-N 0.000 description 1
- VBXIVLPOGQSJOV-UHFFFAOYSA-N 2-(6-bromo-1-benzothiophen-2-yl)acetaldehyde Chemical compound BrC1=CC=C2C=C(CC=O)SC2=C1 VBXIVLPOGQSJOV-UHFFFAOYSA-N 0.000 description 1
- CPHXLFKIUVVIOQ-UHFFFAOYSA-N 2-(trifluoromethoxy)benzaldehyde Chemical compound FC(F)(F)OC1=CC=CC=C1C=O CPHXLFKIUVVIOQ-UHFFFAOYSA-N 0.000 description 1
- YOIAQTFMBZKLLQ-UHFFFAOYSA-N 2-borono-1-benzothiophene-6-carboxylic acid Chemical compound C1=C(C(O)=O)C=C2SC(B(O)O)=CC2=C1 YOIAQTFMBZKLLQ-UHFFFAOYSA-N 0.000 description 1
- BEGREHRAUWCAHV-UHFFFAOYSA-N 2-bromo-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)C1=CSC(Br)=N1 BEGREHRAUWCAHV-UHFFFAOYSA-N 0.000 description 1
- KKZUMAMOMRDVKA-UHFFFAOYSA-N 2-chloropropane Chemical group [CH2]C(C)Cl KKZUMAMOMRDVKA-UHFFFAOYSA-N 0.000 description 1
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 1
- UEKVFLARUBVPKA-UHFFFAOYSA-N 2-iodo-5-methoxyphenol Chemical compound COC1=CC=C(I)C(O)=C1 UEKVFLARUBVPKA-UHFFFAOYSA-N 0.000 description 1
- YCMLQMDWSXFTIF-UHFFFAOYSA-N 2-methylbenzenesulfonimidic acid Chemical compound CC1=CC=CC=C1S(N)(=O)=O YCMLQMDWSXFTIF-UHFFFAOYSA-N 0.000 description 1
- DTALCVXXATYTQJ-UHFFFAOYSA-N 2-propan-2-ylbenzaldehyde Chemical compound CC(C)C1=CC=CC=C1C=O DTALCVXXATYTQJ-UHFFFAOYSA-N 0.000 description 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- HNGQQUDFJDROPY-UHFFFAOYSA-N 3-bromobenzenethiol Chemical compound SC1=CC=CC(Br)=C1 HNGQQUDFJDROPY-UHFFFAOYSA-N 0.000 description 1
- QMVAZEHZOPDGHA-UHFFFAOYSA-N 3-methoxybenzenethiol Chemical compound COC1=CC=CC(S)=C1 QMVAZEHZOPDGHA-UHFFFAOYSA-N 0.000 description 1
- LZPWAYBEOJRFAX-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2$l^{2}-dioxaborolane Chemical compound CC1(C)O[B]OC1(C)C LZPWAYBEOJRFAX-UHFFFAOYSA-N 0.000 description 1
- UCFSYHMCKWNKAH-UHFFFAOYSA-N 4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound CC1(C)OBOC1(C)C UCFSYHMCKWNKAH-UHFFFAOYSA-N 0.000 description 1
- NJOJXJILSQYSRG-UHFFFAOYSA-N 4-(2,6-dichlorophenyl)-1,2-oxazole;5-propan-2-yl-1,2-oxazole Chemical compound CC(C)C1=CC=NO1.ClC1=CC=CC(Cl)=C1C1=CON=C1 NJOJXJILSQYSRG-UHFFFAOYSA-N 0.000 description 1
- PNZIYSWKRBYITO-UHFFFAOYSA-N 4-(bromomethyl)-5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazole Chemical compound ClC1=CC=CC(Cl)=C1C1=NOC(C2CC2)=C1CBr PNZIYSWKRBYITO-UHFFFAOYSA-N 0.000 description 1
- DEZDVAAAZZONAM-UHFFFAOYSA-N 4-(bromomethyl)-5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazole Chemical compound FC(F)(F)OC1=CC=CC=C1C1=NOC(C2CC2)=C1CBr DEZDVAAAZZONAM-UHFFFAOYSA-N 0.000 description 1
- WZXWZXLRMOFOLG-UHFFFAOYSA-N 4-(bromomethyl)-5-cyclopropyl-3-[2-fluoro-6-(trifluoromethyl)phenyl]-1,2-oxazole Chemical compound FC1=CC=CC(C(F)(F)F)=C1C1=NOC(C2CC2)=C1CBr WZXWZXLRMOFOLG-UHFFFAOYSA-N 0.000 description 1
- UPCARQPLANFGQJ-UHFFFAOYSA-N 4-bromo-2-fluorobenzaldehyde Chemical compound FC1=CC(Br)=CC=C1C=O UPCARQPLANFGQJ-UHFFFAOYSA-N 0.000 description 1
- WKWVTPKUHJOVTI-UHFFFAOYSA-N 4-methoxybenzenecarbothioamide Chemical compound COC1=CC=C(C(N)=S)C=C1 WKWVTPKUHJOVTI-UHFFFAOYSA-N 0.000 description 1
- NGTZFWMOTDGMKO-UHFFFAOYSA-N 4-phenyl-1,3-thiazole-5-carboxylic acid Chemical compound S1C=NC(C=2C=CC=CC=2)=C1C(=O)O NGTZFWMOTDGMKO-UHFFFAOYSA-N 0.000 description 1
- TWWNHOGWNKGWAR-UHFFFAOYSA-N 4-propan-2-yl-1h-indole-3-carboxylic acid;5-propan-2-yl-1,2-oxazole Chemical compound CC(C)C1=CC=NO1.CC(C)C1=CC=CC2=C1C(C(O)=O)=CN2 TWWNHOGWNKGWAR-UHFFFAOYSA-N 0.000 description 1
- DWQBOPASRUUSKR-UHFFFAOYSA-N 5-bromo-1-benzothiophene-3-carboxylic acid Chemical compound C1=C(Br)C=C2C(C(=O)O)=CSC2=C1 DWQBOPASRUUSKR-UHFFFAOYSA-N 0.000 description 1
- YAULOOYNCJDPPU-UHFFFAOYSA-N 5-bromo-1h-indole-2-carboxylic acid Chemical compound BrC1=CC=C2NC(C(=O)O)=CC2=C1 YAULOOYNCJDPPU-UHFFFAOYSA-N 0.000 description 1
- COWZPSUDTMGBAT-UHFFFAOYSA-N 5-bromothiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Br)S1 COWZPSUDTMGBAT-UHFFFAOYSA-N 0.000 description 1
- ZTAAVODPVOQJKX-UHFFFAOYSA-N 5-cyclopropyl-1,2-oxazole;4-(2,6-dichlorophenyl)-1,2-oxazole Chemical compound C1CC1C1=CC=NO1.ClC1=CC=CC(Cl)=C1C1=CON=C1 ZTAAVODPVOQJKX-UHFFFAOYSA-N 0.000 description 1
- AIKFVYJYDGAMDM-UHFFFAOYSA-N 5-cyclopropyl-4-[[3-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy]methyl]-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazole Chemical compound C=1C=C(B2OC(C)(C)C(C)(C)O2)C(C)=CC=1OCC=1C(C=2C(=CC=CC=2)OC(F)(F)F)=NOC=1C1CC1 AIKFVYJYDGAMDM-UHFFFAOYSA-N 0.000 description 1
- CENQBZNSQSCMTO-UHFFFAOYSA-N 6-bromo-1-benzothiophene-2-carbaldehyde Chemical compound BrC1=CC=C2C=C(C=O)SC2=C1 CENQBZNSQSCMTO-UHFFFAOYSA-N 0.000 description 1
- HVPQMLZLINVIHW-UHFFFAOYSA-N 6-bromo-1h-indole-2,3-dione Chemical compound BrC1=CC=C2C(=O)C(=O)NC2=C1 HVPQMLZLINVIHW-UHFFFAOYSA-N 0.000 description 1
- BLLMRPOVMOPQKC-UHFFFAOYSA-N 6-methoxy-1-benzofuran-3-one Chemical compound COC1=CC=C2C(=O)COC2=C1 BLLMRPOVMOPQKC-UHFFFAOYSA-N 0.000 description 1
- ROBXWXUVARRLLU-UHFFFAOYSA-N 6-phenylmethoxy-1-benzofuran-2-carboxylic acid Chemical compound C1=C2OC(C(=O)O)=CC2=CC=C1OCC1=CC=CC=C1 ROBXWXUVARRLLU-UHFFFAOYSA-N 0.000 description 1
- FPMICYBCFBLGOZ-UHFFFAOYSA-N 6-phenylmethoxy-1h-indole Chemical compound C=1C=C2C=CNC2=CC=1OCC1=CC=CC=C1 FPMICYBCFBLGOZ-UHFFFAOYSA-N 0.000 description 1
- NOICDPBEDNMHQK-UHFFFAOYSA-N 7-bromo-1-benzothiophene Chemical compound BrC1=CC=CC2=C1SC=C2 NOICDPBEDNMHQK-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229910015845 BBr3 Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- JPCSHBQVGZJFEZ-UHFFFAOYSA-N C(C)OC(=O)C1=CN=CS1.OC1=CC=C(C=C1)C=1SC(=CN1)C(=O)O Chemical compound C(C)OC(=O)C1=CN=CS1.OC1=CC=C(C=C1)C=1SC(=CN1)C(=O)O JPCSHBQVGZJFEZ-UHFFFAOYSA-N 0.000 description 1
- PZQRZXRBAPDFJT-UHFFFAOYSA-N C1(=CC=CC=C1)C=1SC(=CN1)C(=O)O.C1(=CC=CC=C1)C=1N=CSC1C(=O)O Chemical compound C1(=CC=CC=C1)C=1SC(=CN1)C(=O)O.C1(=CC=CC=C1)C=1N=CSC1C(=O)O PZQRZXRBAPDFJT-UHFFFAOYSA-N 0.000 description 1
- GWPNRUMDLXDMGS-UHFFFAOYSA-N CC=1N(C2=CC=CC=C2C1C(=O)O)C.N1C=C(C2=CC=CC=C12)C(=O)O Chemical compound CC=1N(C2=CC=CC=C2C1C(=O)O)C.N1C=C(C2=CC=CC=C12)C(=O)O GWPNRUMDLXDMGS-UHFFFAOYSA-N 0.000 description 1
- DSBYJGYWZNLUJM-UHFFFAOYSA-N CC=1SC(=CN1)C(=O)O.CC=1N=CSC1C(=O)O Chemical compound CC=1SC(=CN1)C(=O)O.CC=1N=CSC1C(=O)O DSBYJGYWZNLUJM-UHFFFAOYSA-N 0.000 description 1
- ADIMFRIXNCDXPV-UHFFFAOYSA-N CN1C=C(C2=CC=CC=C12)C(=O)O.CN1C=C(C2=CC=CC=C12)C(=O)O Chemical compound CN1C=C(C2=CC=CC=C12)C(=O)O.CN1C=C(C2=CC=CC=C12)C(=O)O ADIMFRIXNCDXPV-UHFFFAOYSA-N 0.000 description 1
- PQUJTGZOCRSYNF-UHFFFAOYSA-N COC(=O)C1=C(N(C2=CC=CC=C12)C)C.N1C=C(C2=CC=CC=C12)C(=O)O Chemical compound COC(=O)C1=C(N(C2=CC=CC=C12)C)C.N1C=C(C2=CC=CC=C12)C(=O)O PQUJTGZOCRSYNF-UHFFFAOYSA-N 0.000 description 1
- 101100534223 Caenorhabditis elegans src-1 gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010008635 Cholestasis Diseases 0.000 description 1
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241001328813 Methles Species 0.000 description 1
- PGBFYLVIMDQYMS-UHFFFAOYSA-N Methyl thiophene-2-carboxylate Chemical compound COC(=O)C1=CC=CS1 PGBFYLVIMDQYMS-UHFFFAOYSA-N 0.000 description 1
- WRQNANDWMGAFTP-UHFFFAOYSA-N Methylacetoacetic acid Chemical compound COC(=O)CC(C)=O WRQNANDWMGAFTP-UHFFFAOYSA-N 0.000 description 1
- 238000006751 Mitsunobu reaction Methods 0.000 description 1
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 1
- 108090001146 Nuclear Receptor Coactivator 1 Proteins 0.000 description 1
- 102100037223 Nuclear receptor coactivator 1 Human genes 0.000 description 1
- WJJVMIBWEFAGCC-UHFFFAOYSA-N O1N=C(C2=C1C=CC=C2)C(=O)O.O2N=C(C1=C2C=CC=C1)C(=O)O Chemical compound O1N=C(C2=C1C=CC=C2)C(=O)O.O2N=C(C1=C2C=CC=C1)C(=O)O WJJVMIBWEFAGCC-UHFFFAOYSA-N 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- UUHBLAHCXSFSKR-UHFFFAOYSA-N S1C2=C(C=C1)C=C(C=C2)C(=O)O.S2C1=C(C=C2)C=C(C=C1)C(=O)O Chemical compound S1C2=C(C=C1)C=C(C=C2)C(=O)O.S2C1=C(C=C2)C=C(C=C1)C(=O)O UUHBLAHCXSFSKR-UHFFFAOYSA-N 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 108010069201 VLDL Cholesterol Proteins 0.000 description 1
- 108010062497 VLDL Lipoproteins Proteins 0.000 description 1
- 235000021068 Western diet Nutrition 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- OUKZIJKCWIBRKF-UHFFFAOYSA-N [(2,6-dichlorophenyl)methylideneamino] hypochlorite Chemical compound ClON=CC1=C(Cl)C=CC=C1Cl OUKZIJKCWIBRKF-UHFFFAOYSA-N 0.000 description 1
- KRGFOUGVZFEEBW-UHFFFAOYSA-N [5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methanol Chemical compound OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl KRGFOUGVZFEEBW-UHFFFAOYSA-N 0.000 description 1
- YJPRZVHHSVCUIU-UHFFFAOYSA-N [5-cyclopropyl-3-[2-(trifluoromethoxy)phenyl]-1,2-oxazol-4-yl]methanol Chemical compound OCC1=C(C2CC2)ON=C1C1=CC=CC=C1OC(F)(F)F YJPRZVHHSVCUIU-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- LKGAKRUPGMUHAQ-UHFFFAOYSA-N acetonitrile thiophene-2-carboxylic acid Chemical compound CC#N.OC(=O)c1cccs1 LKGAKRUPGMUHAQ-UHFFFAOYSA-N 0.000 description 1
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000008484 agonism Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 238000012440 amplified luminescent proximity homogeneous assay Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 125000005603 azodicarboxylic group Chemical group 0.000 description 1
- 150000003935 benzaldehydes Chemical class 0.000 description 1
- KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
- 229940073608 benzyl chloride Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- ODWXUNBKCRECNW-UHFFFAOYSA-M bromocopper(1+) Chemical compound Br[Cu+] ODWXUNBKCRECNW-UHFFFAOYSA-M 0.000 description 1
- 125000003865 brosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Br)S(*)(=O)=O 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- OVIZSQRQYWEGON-UHFFFAOYSA-N butane-1-sulfonamide Chemical compound CCCCS(N)(=O)=O OVIZSQRQYWEGON-UHFFFAOYSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002837 carbocyclic group Chemical group 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 230000036996 cardiovascular health Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000012320 chlorinating reagent Substances 0.000 description 1
- 238000005660 chlorination reaction Methods 0.000 description 1
- 125000002603 chloroethyl group Chemical group [H]C([*])([H])C([H])([H])Cl 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229910052681 coesite Inorganic materials 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 229910052906 cristobalite Inorganic materials 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- IIJREXIVDSIOFR-UHFFFAOYSA-N dichloromethane;heptane Chemical compound ClCCl.CCCCCCC IIJREXIVDSIOFR-UHFFFAOYSA-N 0.000 description 1
- SPWVRYZQLGQKGK-UHFFFAOYSA-N dichloromethane;hexane Chemical compound ClCCl.CCCCCC SPWVRYZQLGQKGK-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- ZCRZCMUDOWDGOB-UHFFFAOYSA-N ethanesulfonimidic acid Chemical compound CCS(N)(=O)=O ZCRZCMUDOWDGOB-UHFFFAOYSA-N 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 1
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 description 1
- XDOKFEJMEJKVGX-UHFFFAOYSA-N ethyl 1,3-thiazole-4-carboxylate Chemical compound CCOC(=O)C1=CSC=N1 XDOKFEJMEJKVGX-UHFFFAOYSA-N 0.000 description 1
- JNLHHFVLQDYFFB-UHFFFAOYSA-N ethyl 1-benzofuran-3-carboxylate Chemical compound C1=CC=C2C(C(=O)OCC)=COC2=C1 JNLHHFVLQDYFFB-UHFFFAOYSA-N 0.000 description 1
- DZYVXFNCEKBKJL-UHFFFAOYSA-N ethyl 1-cyclopropyl-5-hydroxy-2-methylindole-3-carboxylate Chemical compound C12=CC=C(O)C=C2C(C(=O)OCC)=C(C)N1C1CC1 DZYVXFNCEKBKJL-UHFFFAOYSA-N 0.000 description 1
- APLMITABUYLAMR-UHFFFAOYSA-N ethyl 2-(4-hydroxy-2-methylphenyl)-4-propan-2-yl-1,3-thiazole-5-carboxylate Chemical compound CC(C)C1=C(C(=O)OCC)SC(C=2C(=CC(O)=CC=2)C)=N1 APLMITABUYLAMR-UHFFFAOYSA-N 0.000 description 1
- XGOWYXHVRJISDX-UHFFFAOYSA-N ethyl 2-(6-hydroxy-1-benzothiophen-3-yl)acetate Chemical compound OC1=CC=C2C(CC(=O)OCC)=CSC2=C1 XGOWYXHVRJISDX-UHFFFAOYSA-N 0.000 description 1
- WASLOYGXYDURDY-UHFFFAOYSA-N ethyl 2-[6-(trifluoromethylsulfonyloxy)-1-benzothiophen-3-yl]acetate Chemical compound FC(F)(F)S(=O)(=O)OC1=CC=C2C(CC(=O)OCC)=CSC2=C1 WASLOYGXYDURDY-UHFFFAOYSA-N 0.000 description 1
- XJRPTMORGOIMMI-UHFFFAOYSA-N ethyl 2-amino-4-(trifluoromethyl)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C(F)(F)F XJRPTMORGOIMMI-UHFFFAOYSA-N 0.000 description 1
- OZMXFXOHCUEEPD-UHFFFAOYSA-N ethyl 2-amino-4-phenyl-1,3-thiazole-5-carboxylate Chemical compound S1C(N)=NC(C=2C=CC=CC=2)=C1C(=O)OCC OZMXFXOHCUEEPD-UHFFFAOYSA-N 0.000 description 1
- JTRJDESRRBKKDQ-UHFFFAOYSA-N ethyl 2-amino-4-propyl-1,3-thiazole-5-carboxylate Chemical compound CCCC=1N=C(N)SC=1C(=O)OCC JTRJDESRRBKKDQ-UHFFFAOYSA-N 0.000 description 1
- UONWSWFRDMODNB-UHFFFAOYSA-N ethyl 2-amino-5-propan-2-yl-1,3-thiazole-4-carboxylate Chemical compound CCOC(=O)C=1N=C(N)SC=1C(C)C UONWSWFRDMODNB-UHFFFAOYSA-N 0.000 description 1
- KTYIFXLNIMPSKI-UHFFFAOYSA-N ethyl 2-bromo-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(Br)S1 KTYIFXLNIMPSKI-UHFFFAOYSA-N 0.000 description 1
- CFVZERGDGYZJHR-UHFFFAOYSA-N ethyl 2-bromo-4-propan-2-yl-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(Br)=NC=1C(C)C CFVZERGDGYZJHR-UHFFFAOYSA-N 0.000 description 1
- RDULEYWUGKOCMR-UHFFFAOYSA-N ethyl 2-chloro-3-oxobutanoate Chemical compound CCOC(=O)C(Cl)C(C)=O RDULEYWUGKOCMR-UHFFFAOYSA-N 0.000 description 1
- PVBRSNZAOAJRKO-UHFFFAOYSA-N ethyl 2-sulfanylacetate Chemical compound CCOC(=O)CS PVBRSNZAOAJRKO-UHFFFAOYSA-N 0.000 description 1
- OHLRLMWUFVDREV-UHFFFAOYSA-N ethyl 4-chloro-3-oxobutanoate Chemical compound CCOC(=O)CC(=O)CCl OHLRLMWUFVDREV-UHFFFAOYSA-N 0.000 description 1
- XCLDSQRVMMXWMS-UHFFFAOYSA-N ethyl 4-methyl-3-oxopentanoate Chemical compound CCOC(=O)CC(=O)C(C)C XCLDSQRVMMXWMS-UHFFFAOYSA-N 0.000 description 1
- TVTVDJCEYSHIRP-UHFFFAOYSA-N ethyl 5-(4-hydroxy-2-methylphenyl)-1-benzofuran-2-carboxylate Chemical compound C=1C=C2OC(C(=O)OCC)=CC2=CC=1C1=CC=C(O)C=C1C TVTVDJCEYSHIRP-UHFFFAOYSA-N 0.000 description 1
- XLJWAHXKBCDQNP-UHFFFAOYSA-N ethyl 5-bromo-1-benzofuran-2-carboxylate Chemical compound BrC1=CC=C2OC(C(=O)OCC)=CC2=C1 XLJWAHXKBCDQNP-UHFFFAOYSA-N 0.000 description 1
- ADEQGMXEHRCMKL-UHFFFAOYSA-N ethyl 6-bromo-1,2-benzoxazole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OCC)=NOC2=C1 ADEQGMXEHRCMKL-UHFFFAOYSA-N 0.000 description 1
- QNZMCEMVNKFVOA-UHFFFAOYSA-N ethyl 6-bromo-1-benzothiophene-2-carboxylate Chemical compound C1=C(Br)C=C2SC(C(=O)OCC)=CC2=C1 QNZMCEMVNKFVOA-UHFFFAOYSA-N 0.000 description 1
- POLGDYGGGGODRD-UHFFFAOYSA-N ethyl 6-bromo-1-benzothiophene-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OCC)=CSC2=C1 POLGDYGGGGODRD-UHFFFAOYSA-N 0.000 description 1
- DEWFEMVAEWTLQM-UHFFFAOYSA-N ethyl 6-bromo-1-cyclopropyl-5-hydroxy-2-methylindole-3-carboxylate Chemical compound C12=CC(Br)=C(O)C=C2C(C(=O)OCC)=C(C)N1C1CC1 DEWFEMVAEWTLQM-UHFFFAOYSA-N 0.000 description 1
- RXPGUNOYNYVCGK-UHFFFAOYSA-N ethyl 6-hydroxy-1-benzofuran-3-carboxylate Chemical compound OC1=CC=C2C(C(=O)OCC)=COC2=C1 RXPGUNOYNYVCGK-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- ZDGGJQMSELMHLK-UHFFFAOYSA-N m-Trifluoromethylhippuric acid Chemical compound OC(=O)CNC(=O)C1=CC=CC(C(F)(F)F)=C1 ZDGGJQMSELMHLK-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
- SJFNDMHZXCUXSA-UHFFFAOYSA-M methoxymethyl(triphenyl)phosphanium;chloride Chemical compound [Cl-].C=1C=CC=CC=1[P+](C=1C=CC=CC=1)(COC)C1=CC=CC=C1 SJFNDMHZXCUXSA-UHFFFAOYSA-M 0.000 description 1
- JOMFWLPNQBFZEX-UHFFFAOYSA-N methyl 1,2-benzothiazole-3-carboxylate Chemical compound C1=CC=C2C(C(=O)OC)=NSC2=C1 JOMFWLPNQBFZEX-UHFFFAOYSA-N 0.000 description 1
- MFMNLSWDVPSGBL-UHFFFAOYSA-N methyl 1-benzothiophene-7-carboxylate Chemical compound COC(=O)C1=CC=CC2=C1SC=C2 MFMNLSWDVPSGBL-UHFFFAOYSA-N 0.000 description 1
- UDYWPDSXKAEITG-UHFFFAOYSA-N methyl 2-(1-methyl-6-phenylmethoxyindol-3-yl)-2-oxoacetate Chemical compound C=1C=C2C(C(=O)C(=O)OC)=CN(C)C2=CC=1OCC1=CC=CC=C1 UDYWPDSXKAEITG-UHFFFAOYSA-N 0.000 description 1
- KHXUTOLCCFWPDH-UHFFFAOYSA-N methyl 2-(4-bromo-2-nitrophenyl)acetate Chemical compound COC(=O)CC1=CC=C(Br)C=C1[N+]([O-])=O KHXUTOLCCFWPDH-UHFFFAOYSA-N 0.000 description 1
- SSWHBDSYYMBTKI-UHFFFAOYSA-N methyl 2-(5-bromo-1h-indol-3-yl)acetate Chemical compound C1=C(Br)C=C2C(CC(=O)OC)=CNC2=C1 SSWHBDSYYMBTKI-UHFFFAOYSA-N 0.000 description 1
- AEEJJCJGHRTVRI-UHFFFAOYSA-N methyl 2-(6-bromo-1-benzothiophen-2-yl)acetate Chemical compound C1=C(Br)C=C2SC(CC(=O)OC)=CC2=C1 AEEJJCJGHRTVRI-UHFFFAOYSA-N 0.000 description 1
- YQEATBQCQHPLHL-UHFFFAOYSA-N methyl 2-(6-hydroxy-1-methylindol-3-yl)acetate Chemical compound OC1=CC=C2C(CC(=O)OC)=CN(C)C2=C1 YQEATBQCQHPLHL-UHFFFAOYSA-N 0.000 description 1
- RIJWDPRXCXJDPK-UHFFFAOYSA-N methyl 3-cyclopropyl-3-oxopropanoate Chemical compound COC(=O)CC(=O)C1CC1 RIJWDPRXCXJDPK-UHFFFAOYSA-N 0.000 description 1
- BRWROFVPMUPMJQ-UHFFFAOYSA-N methyl 3-methylthiophene-2-carboxylate Chemical compound COC(=O)C=1SC=CC=1C BRWROFVPMUPMJQ-UHFFFAOYSA-N 0.000 description 1
- COVWTINOAVASMD-UHFFFAOYSA-N methyl 5-(2-chloro-4-hydroxyphenyl)-4-methylthiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC(C)=C1C1=CC=C(O)C=C1Cl COVWTINOAVASMD-UHFFFAOYSA-N 0.000 description 1
- KQHSDTRELVCLHW-UHFFFAOYSA-N methyl 5-(2-chloro-4-hydroxyphenyl)thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1C1=CC=C(O)C=C1Cl KQHSDTRELVCLHW-UHFFFAOYSA-N 0.000 description 1
- JXIFTJPLXDAQGY-UHFFFAOYSA-N methyl 5-(4-hydroxy-2-methylphenyl)-1h-indole-3-carboxylate Chemical compound C1=C2C(C(=O)OC)=CNC2=CC=C1C1=CC=C(O)C=C1C JXIFTJPLXDAQGY-UHFFFAOYSA-N 0.000 description 1
- ZCPCZELMTZDPAK-UHFFFAOYSA-N methyl 5-(4-hydroxy-2-methylphenyl)-4-methylthiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC(C)=C1C1=CC=C(O)C=C1C ZCPCZELMTZDPAK-UHFFFAOYSA-N 0.000 description 1
- AALWVKQRLXHHRT-UHFFFAOYSA-N methyl 5-(4-methoxy-2-methylphenyl)-4-methylthiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC(C)=C1C1=CC=C(OC)C=C1C AALWVKQRLXHHRT-UHFFFAOYSA-N 0.000 description 1
- LOYPKNMDUNGIOF-UHFFFAOYSA-N methyl 5-[4-[[5-cyclopropyl-3-(2,6-dichlorophenyl)-1,2-oxazol-4-yl]methoxy]-2-methylphenyl]thiophene-2-carboxylate Chemical compound S1C(C(=O)OC)=CC=C1C(C(=C1)C)=CC=C1OCC1=C(C2CC2)ON=C1C1=C(Cl)C=CC=C1Cl LOYPKNMDUNGIOF-UHFFFAOYSA-N 0.000 description 1
- QZNZVRWWWOWDRV-UHFFFAOYSA-N methyl 5-bromo-1-benzothiophene-3-carboxylate Chemical compound C1=C(Br)C=C2C(C(=O)OC)=CSC2=C1 QZNZVRWWWOWDRV-UHFFFAOYSA-N 0.000 description 1
- QLWUHAQCKDHUNL-UHFFFAOYSA-N methyl 5-bromothiophene-2-carboxylate Chemical compound COC(=O)C1=CC=C(Br)S1 QLWUHAQCKDHUNL-UHFFFAOYSA-N 0.000 description 1
- KGVJNBAZSXTWJW-UHFFFAOYSA-N methyl 6-(4-hydroxy-2-methylphenyl)-1-(2-methylsulfanylethyl)indole-3-carboxylate Chemical compound C=1C=C2C(C(=O)OC)=CN(CCSC)C2=CC=1C1=CC=C(O)C=C1C KGVJNBAZSXTWJW-UHFFFAOYSA-N 0.000 description 1
- XXEWKZYLPOJIIL-UHFFFAOYSA-N methyl 6-(4-hydroxy-2-methylphenyl)-1-propan-2-ylindole-3-carboxylate Chemical compound C=1C=C2C(C(=O)OC)=CN(C(C)C)C2=CC=1C1=CC=C(O)C=C1C XXEWKZYLPOJIIL-UHFFFAOYSA-N 0.000 description 1
- ASHFLMVXCNOCHI-UHFFFAOYSA-N methyl 6-(4-hydroxy-2-methylphenyl)-1h-indole-2-carboxylate Chemical compound C1=C2NC(C(=O)OC)=CC2=CC=C1C1=CC=C(O)C=C1C ASHFLMVXCNOCHI-UHFFFAOYSA-N 0.000 description 1
- POIZYKIPHOHXDG-UHFFFAOYSA-N methyl 6-(4-hydroxy-2-methylphenyl)-2-methyl-1-propan-2-ylindole-3-carboxylate Chemical compound C=1C=C2C(C(=O)OC)=C(C)N(C(C)C)C2=CC=1C1=CC=C(O)C=C1C POIZYKIPHOHXDG-UHFFFAOYSA-N 0.000 description 1
- POUNGHPAZUJZNT-UHFFFAOYSA-N methyl 6-bromo-1-(2-methylsulfanylethyl)indole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OC)=CN(CCSC)C2=C1 POUNGHPAZUJZNT-UHFFFAOYSA-N 0.000 description 1
- VPDDVKPIOCFHRM-UHFFFAOYSA-N methyl 6-bromo-1-benzothiophene-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OC)=CSC2=C1 VPDDVKPIOCFHRM-UHFFFAOYSA-N 0.000 description 1
- JYORQPYGJQXAML-UHFFFAOYSA-N methyl 6-bromo-1-butylindole-3-carboxylate Chemical compound C1=C(Br)C=C2N(CCCC)C=C(C(=O)OC)C2=C1 JYORQPYGJQXAML-UHFFFAOYSA-N 0.000 description 1
- RCDWEKOOOHATJC-UHFFFAOYSA-N methyl 6-bromo-1-methylindole-2-carboxylate Chemical compound C1=C(Br)C=C2N(C)C(C(=O)OC)=CC2=C1 RCDWEKOOOHATJC-UHFFFAOYSA-N 0.000 description 1
- RUBYSVHZXJRNLS-UHFFFAOYSA-N methyl 6-bromo-1-propan-2-ylindazole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OC)=NN(C(C)C)C2=C1 RUBYSVHZXJRNLS-UHFFFAOYSA-N 0.000 description 1
- HVSAEJIBGMVUJK-UHFFFAOYSA-N methyl 6-bromo-1-propan-2-ylindole-3-carboxylate Chemical compound BrC1=CC=C2C(C(=O)OC)=CN(C(C)C)C2=C1 HVSAEJIBGMVUJK-UHFFFAOYSA-N 0.000 description 1
- RMEDXVIWDFLGES-UHFFFAOYSA-N methyl 6-chloropyridine-3-carboxylate Chemical compound COC(=O)C1=CC=C(Cl)N=C1 RMEDXVIWDFLGES-UHFFFAOYSA-N 0.000 description 1
- ODAVTXGNQNWWJZ-UHFFFAOYSA-N methyl 6-hydroxy-2-methyl-1-benzofuran-3-carboxylate Chemical compound OC1=CC=C2C(C(=O)OC)=C(C)OC2=C1 ODAVTXGNQNWWJZ-UHFFFAOYSA-N 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- OQJBFFCUFALWQL-UHFFFAOYSA-N n-(piperidine-1-carbonylimino)piperidine-1-carboxamide Chemical compound C1CCCCN1C(=O)N=NC(=O)N1CCCCC1 OQJBFFCUFALWQL-UHFFFAOYSA-N 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- HNDXKIMMSFCCFW-UHFFFAOYSA-N propane-2-sulphonic acid Chemical compound CC(C)S(O)(=O)=O HNDXKIMMSFCCFW-UHFFFAOYSA-N 0.000 description 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- MWWATHDPGQKSAR-UHFFFAOYSA-N propyne Chemical compound CC#C MWWATHDPGQKSAR-UHFFFAOYSA-N 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000001235 sensitizing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- UKLNMMHNWFDKNT-UHFFFAOYSA-M sodium chlorite Chemical compound [Na+].[O-]Cl=O UKLNMMHNWFDKNT-UHFFFAOYSA-M 0.000 description 1
- 229960002218 sodium chlorite Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000009518 sodium iodide Nutrition 0.000 description 1
- KOUDKOMXLMXFKX-UHFFFAOYSA-N sodium oxido(oxo)phosphanium hydrate Chemical compound O.[Na+].[O-][PH+]=O KOUDKOMXLMXFKX-UHFFFAOYSA-N 0.000 description 1
- 239000011877 solvent mixture Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 229910052682 stishovite Inorganic materials 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 125000001273 sulfonato group Chemical class [O-]S(*)(=O)=O 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- GKJLTLRSQRRBNI-UHFFFAOYSA-N tert-butyl 6-(4-hydroxy-2-methylphenyl)-1-benzofuran-3-carboxylate Chemical compound CC1=CC(O)=CC=C1C1=CC=C(C(=CO2)C(=O)OC(C)(C)C)C2=C1 GKJLTLRSQRRBNI-UHFFFAOYSA-N 0.000 description 1
- XCFSBSSAXYTVSV-UHFFFAOYSA-N tert-butyl 6-phenylmethoxy-1-benzofuran-2-carboxylate Chemical compound C1=C2OC(C(=O)OC(C)(C)C)=CC2=CC=C1OCC1=CC=CC=C1 XCFSBSSAXYTVSV-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 125000002088 tosyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])[H])S(*)(=O)=O 0.000 description 1
- 229910052905 tridymite Inorganic materials 0.000 description 1
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical compound OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 description 1
- 229910000404 tripotassium phosphate Inorganic materials 0.000 description 1
- 235000019798 tripotassium phosphate Nutrition 0.000 description 1
- NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US76540706P | 2006-02-03 | 2006-02-03 | |
| US60/765,407 | 2006-02-03 | ||
| US80631006P | 2006-06-30 | 2006-06-30 | |
| US60/806,310 | 2006-06-30 | ||
| PCT/US2007/061515 WO2007092751A2 (en) | 2006-02-03 | 2007-02-02 | Compounds and methods for modulating fx-receptors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2007212126A1 AU2007212126A1 (en) | 2007-08-16 |
| AU2007212126B2 true AU2007212126B2 (en) | 2012-07-19 |
Family
ID=38229980
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2007212126A Ceased AU2007212126B2 (en) | 2006-02-03 | 2007-02-02 | Compounds and methods for modulating FX-receptors |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7863302B2 (https=) |
| EP (1) | EP1984360B1 (https=) |
| JP (1) | JP5301286B2 (https=) |
| CN (1) | CN101374834B (https=) |
| AU (1) | AU2007212126B2 (https=) |
| BR (1) | BRPI0707427A2 (https=) |
| CA (1) | CA2640476A1 (https=) |
| ES (1) | ES2452031T3 (https=) |
| WO (1) | WO2007092751A2 (https=) |
Families Citing this family (89)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007076260A2 (en) * | 2005-12-19 | 2007-07-05 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
| KR101130380B1 (ko) * | 2006-06-13 | 2012-04-23 | 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 | 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도 |
| KR20100038102A (ko) * | 2007-06-13 | 2010-04-12 | 글락소스미스클라인 엘엘씨 | 파네소이드 x 수용체 작용제 |
| TW200906823A (en) | 2007-07-16 | 2009-02-16 | Lilly Co Eli | Compounds and methods for modulating FXR |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| KR101175859B1 (ko) | 2007-12-04 | 2012-08-24 | 에프. 호프만-라 로슈 아게 | 이속사졸로-피라진 유도체 |
| US7902201B2 (en) | 2007-12-04 | 2011-03-08 | Hoffmann-La Roche Inc. | Isoxazolo-pyrazine derivatives |
| EP2128158A1 (en) | 2008-05-26 | 2009-12-02 | Phenex Pharmaceuticals AG | Heterocyclic cyclopropyl-substituted FXR binding compounds |
| HUE025013T2 (hu) | 2009-01-12 | 2016-04-28 | Pfizer Ltd | Szulfonamid-származékok |
| TW201033201A (en) | 2009-02-19 | 2010-09-16 | Hoffmann La Roche | Isoxazole-isoxazole and isoxazole-isothiazole derivatives |
| US8389550B2 (en) | 2009-02-25 | 2013-03-05 | Hoffmann-La Roche Inc. | Isoxazoles / O-pyridines with ethyl and ethenyl linker |
| US8222246B2 (en) | 2009-04-02 | 2012-07-17 | Hoffmann-La Roche Inc. | Substituted isoxazoles |
| US20100280019A1 (en) | 2009-04-30 | 2010-11-04 | Roland Jakob-Roetne | Isoxazoles |
| JP5460858B2 (ja) | 2009-05-05 | 2014-04-02 | エフ.ホフマン−ラ ロシュ アーゲー | イソオキサゾール−ピラゾール誘導体 |
| CA2760597C (en) | 2009-05-05 | 2017-08-22 | F. Hoffmann-La Roche Ag | Isoxazole-pyridazine derivatives |
| CA2759598C (en) | 2009-05-05 | 2017-09-12 | F. Hoffmann-La Roche Ag | Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders |
| KR101367012B1 (ko) | 2009-05-05 | 2014-03-14 | 에프. 호프만-라 로슈 아게 | 이속사졸-피리딘 유도체 |
| BRPI1013766A2 (pt) | 2009-05-07 | 2016-04-05 | Hoffmann La Roche | "derivados de isoxazol-piridina como moduladores de gaba" |
| EP2289883A1 (en) | 2009-08-19 | 2011-03-02 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| CA2799154A1 (en) | 2010-05-12 | 2011-11-17 | Abbvie Inc. | Indazole inhibitors of kinase |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| EP2655368A1 (en) * | 2010-12-20 | 2013-10-30 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| WO2012087521A1 (en) * | 2010-12-20 | 2012-06-28 | Irm Llc | Compositions and methods for modulating farnesoid x receptors |
| ES2594409T3 (es) | 2011-02-23 | 2016-12-20 | Lupin Limited | Derivados de heteroarilo como moduladores del nAChR á7 |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2729455B1 (en) | 2011-07-05 | 2016-09-14 | Lupin Limited | Biaryl derivatives as nachr modulators |
| EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
| WO2013037482A1 (en) | 2011-09-15 | 2013-03-21 | Phenex Pharmaceuticals Ag | Farnesoid x receptor agonists for cancer treatment and prevention |
| US8785435B2 (en) | 2011-10-20 | 2014-07-22 | Hoffmann-La Roche Inc. | Solid forms |
| JP6106179B2 (ja) | 2012-02-24 | 2017-03-29 | 武田薬品工業株式会社 | 芳香環化合物 |
| NZ629453A (en) | 2012-03-06 | 2016-04-29 | Lupin Ltd | Thiazole derivatives as alpha 7 nachr modulators |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| JP6064062B2 (ja) | 2013-03-15 | 2017-01-18 | ファイザー・インク | Ampkを活性化させるインダゾール化合物 |
| DK3043865T3 (da) | 2013-09-11 | 2021-02-01 | Univ Claude Bernard Lyon | Fremgangsmåder og farmaceutiske sammensætningr til behandlingen af hepatitis b-virusinfektion |
| EP3006939A1 (en) | 2014-10-06 | 2016-04-13 | Gilead Sciences, Inc. | Histidine-rich Glycoprotein as a marker for hepatic Farnesoid X receptor activation |
| US10208081B2 (en) | 2014-11-26 | 2019-02-19 | Enanta Pharmaceuticals, Inc. | Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof |
| MA41094A (fr) | 2014-12-02 | 2017-10-10 | Lilly Co Eli | Procédés de traitement de troubles rénaux |
| EP3034501A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Hydroxy containing FXR (NR1H4) modulating compounds |
| EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
| TWI698430B (zh) | 2015-02-13 | 2020-07-11 | 南北兄弟藥業投資有限公司 | 三環化合物及其在藥物中的應用 |
| WO2016161003A1 (en) | 2015-03-31 | 2016-10-06 | Enanta Phamraceuticals, Inc. | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof |
| CN106995416A (zh) * | 2016-01-26 | 2017-08-01 | 上海翰森生物医药科技有限公司 | Fxr激动剂及其制备方法和应用 |
| WO2017128896A1 (zh) * | 2016-01-26 | 2017-08-03 | 江苏豪森药业集团有限公司 | Fxr激动剂及其制备方法和应用 |
| WO2017189663A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| US10080741B2 (en) | 2016-04-26 | 2018-09-25 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| WO2017189651A1 (en) | 2016-04-26 | 2017-11-02 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201152A1 (en) * | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| WO2017201155A1 (en) * | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | lSOXAZOLE DERIVATIVES AS FXR AGONISTS AND METHODS OF USE THEREOF |
| WO2017201150A1 (en) * | 2016-05-18 | 2017-11-23 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| CA3252823A1 (en) | 2016-06-13 | 2025-02-25 | Gilead Sciences, Inc. | Substituted tert-butyl-3-(2-chloro-phenyl)-3-hydroxyazetidine-1-carboxylate compounds |
| MX385718B (es) | 2016-06-13 | 2025-03-18 | Gilead Sciences Inc | Compuestos moduladores de fxr (nr1h4). |
| TW201808283A (zh) | 2016-08-05 | 2018-03-16 | 廣東東陽光藥業有限公司 | 含氮三環化合物及其在藥物中的應用 |
| US10450306B2 (en) * | 2016-10-04 | 2019-10-22 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as FXR agonists and methods of use thereof |
| WO2018081285A1 (en) | 2016-10-26 | 2018-05-03 | Enanta Pharmaceuticals, Inc. | Urea-containing isoxazole derivatives as fxr agonists and methods of use thereof |
| CN108017636A (zh) * | 2016-11-04 | 2018-05-11 | 合帕吉恩治疗公司 | 作为fxr调节剂的含氮杂环化合物 |
| CN108218852A (zh) * | 2016-12-15 | 2018-06-29 | 宁波百纳西药业有限公司 | 一种螺环化合物、其制备方法、组合物及用途 |
| WO2018133730A1 (zh) * | 2017-01-20 | 2018-07-26 | 四川科伦博泰生物医药股份有限公司 | 一种杂环化合物及其制备方法和用途 |
| PT3600309T (pt) | 2017-03-28 | 2022-10-03 | Gilead Sciences Inc | Combinações terapêuticas para o tratamento de doenças hepáticas |
| WO2018178260A1 (en) | 2017-03-30 | 2018-10-04 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing persistence and expression of episomal viruses |
| PL3612520T3 (pl) | 2017-04-12 | 2022-03-21 | Il Dong Pharmaceutical Co., Ltd. | Pochodne izoksazolu jako agoniści receptora jądrowego i ich zastosowania |
| CN106977535A (zh) * | 2017-04-28 | 2017-07-25 | 大连联化化学有限公司 | 一种合成2‑氰基3‑氟苯硼酸工艺 |
| CN109575008B (zh) * | 2017-09-29 | 2020-11-17 | 轩竹生物科技有限公司 | Fxr受体激动剂 |
| AU2018360575A1 (en) | 2017-11-01 | 2020-06-18 | Bristol-Myers Squibb Company | Alkene spirocyclic compounds as farnesoid X receptor modulators |
| CN111278817B (zh) | 2017-11-01 | 2023-05-16 | 百时美施贵宝公司 | 作为法尼醇x受体调节剂的多环化合物 |
| CN111511731B (zh) | 2017-11-01 | 2023-05-23 | 百时美施贵宝公司 | 作为法尼醇x受体调节剂的烯烃化合物 |
| WO2019118571A1 (en) | 2017-12-12 | 2019-06-20 | Enanta Pharmaceuticals, Inc. | Isoxazole analogs as fxr agonists and methods of use thereof |
| CN110128432B (zh) | 2018-02-02 | 2021-03-02 | 广东东阳光药业有限公司 | 含氮三环化合物及其在药物中的应用 |
| US10829486B2 (en) | 2018-02-14 | 2020-11-10 | Enanta Pharmacueticals, Inc. | Isoxazole derivatives as FXR agonists and methods of use thereof |
| EP3911647B1 (en) | 2019-01-15 | 2023-12-13 | Gilead Sciences, Inc. | Isoxazole compound as fxr agonist and pharmaceutical compositions comprising same |
| CA3233305A1 (en) | 2019-02-19 | 2020-08-27 | Gilead Sciences, Inc. | Solid forms of fxr agonists |
| CN111825667B (zh) * | 2019-04-19 | 2023-07-25 | 中国科学院上海药物研究所 | Fxr小分子激动剂及其制备方法和用途 |
| WO2020231917A1 (en) | 2019-05-13 | 2020-11-19 | Enanta Pharmaceuticals, Inc. | Isoxazole derivatives as fxr agonists and methods of use thereof |
| KR20220035365A (ko) | 2019-07-18 | 2022-03-22 | 엔요 파마 | 인터페론의 부작용을 감소시키는 방법 |
| WO2021108974A1 (en) | 2019-12-03 | 2021-06-10 | Gannex Pharma Co., Ltd | Compounds for modulating activity of fxr and uses thereof |
| CN111004211B (zh) * | 2019-12-29 | 2021-04-02 | 苏州诚和医药化学有限公司 | 一种依匹哌唑中间体4-溴苯并[b]噻吩的合成方法 |
| WO2021145543A1 (ko) * | 2020-01-15 | 2021-07-22 | 재단법인 대구경북과학기술원 | 세포외 기질 및 항암제로 이루어진 접합체 및 이의 의학적 용도 |
| IL293892A (en) | 2020-01-15 | 2022-08-01 | Inserm Institut National De La Sant? Et De La Rech M?Dicale | Use of fxr agonists for treating an infection by hepatitis d virus |
| JP2024502673A (ja) | 2021-01-14 | 2024-01-22 | ウエヌイグレックオ・ファーマ | Hbv感染の処置のためのfxrアゴニストとifnの相乗効果 |
| CN112876516B (zh) * | 2021-02-05 | 2022-02-15 | 昆明理工大学 | N-(4-吲哚基)氮杂环卡宾钯络合物及应用 |
| CN112898247B (zh) * | 2021-03-09 | 2023-03-14 | 中国科学院兰州化学物理研究所 | 一种呋喃乙酸酯类化合物的合成方法 |
| JP2024517181A (ja) | 2021-04-28 | 2024-04-19 | ウエヌイグレックオ・ファーマ | 組合せ治療としてfxrアゴニストを使用するtlr3アゴニストの効果の強い増強 |
| CN116425716A (zh) * | 2021-12-31 | 2023-07-14 | 南京艾德凯腾生物医药有限责任公司 | 一种依匹哌唑中间体的制备方法 |
| CN115850152B (zh) * | 2022-12-20 | 2025-10-31 | 河北鼎泰制药有限公司 | 一种杂质A-7-imp3的制备方法及其用途 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004048349A1 (en) * | 2002-11-22 | 2004-06-10 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
| ATE381542T1 (de) * | 2001-08-13 | 2008-01-15 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| WO2007076260A2 (en) * | 2005-12-19 | 2007-07-05 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
-
2007
- 2007-02-02 CA CA002640476A patent/CA2640476A1/en not_active Abandoned
- 2007-02-02 ES ES07763142.2T patent/ES2452031T3/es active Active
- 2007-02-02 EP EP07763142.2A patent/EP1984360B1/en active Active
- 2007-02-02 AU AU2007212126A patent/AU2007212126B2/en not_active Ceased
- 2007-02-02 WO PCT/US2007/061515 patent/WO2007092751A2/en not_active Ceased
- 2007-02-02 CN CN2007800038562A patent/CN101374834B/zh not_active Expired - Fee Related
- 2007-02-02 JP JP2008553518A patent/JP5301286B2/ja active Active
- 2007-02-02 BR BRPI0707427-1A patent/BRPI0707427A2/pt not_active IP Right Cessation
- 2007-02-02 US US12/159,224 patent/US7863302B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004048349A1 (en) * | 2002-11-22 | 2004-06-10 | Smithkline Beecham Corporation | Farnesoid x receptor agonists |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101374834A (zh) | 2009-02-25 |
| US7863302B2 (en) | 2011-01-04 |
| JP5301286B2 (ja) | 2013-09-25 |
| WO2007092751A2 (en) | 2007-08-16 |
| CN101374834B (zh) | 2011-12-14 |
| ES2452031T3 (es) | 2014-03-31 |
| AU2007212126A1 (en) | 2007-08-16 |
| BRPI0707427A2 (pt) | 2011-05-03 |
| EP1984360A2 (en) | 2008-10-29 |
| CA2640476A1 (en) | 2007-08-16 |
| WO2007092751A3 (en) | 2007-12-27 |
| JP2009525984A (ja) | 2009-07-16 |
| US20080306125A1 (en) | 2008-12-11 |
| EP1984360B1 (en) | 2014-01-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2007212126B2 (en) | Compounds and methods for modulating FX-receptors | |
| CN101180290B (zh) | 氢化苯并〔c〕噻吩衍生物作为免疫调节剂 | |
| US8093278B2 (en) | Substituted indoles | |
| US6787651B2 (en) | Substituted indoles, pharmaceutical compounds containing such indoles and their use as PPAR-γ binding agents | |
| JP5115474B2 (ja) | 消化管潰瘍治療又は予防薬 | |
| JP5040656B2 (ja) | トリアリールカルボン酸誘導体 | |
| CN102149680B (zh) | 含氮芳族杂环化合物 | |
| KR20100044810A (ko) | 파네소이드 x 수용체 효능제 | |
| JP2009529005A (ja) | アンジオテンシン1受容体(at1)とエンドセリンa(eta)受容体に対する新規な二重作用受容体拮抗薬(dara) | |
| CN1802154A (zh) | 吡啶n-氧化物抗病毒药 | |
| JP4894517B2 (ja) | 2−フェニルピリジン誘導体 | |
| JPWO2008016175A1 (ja) | ペルオキシソーム増殖剤活性化受容体の活性化剤 | |
| EP1812426B1 (en) | Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease | |
| JPWO2006022375A1 (ja) | 2−フェニルチオフェン誘導体 | |
| CN105189476A (zh) | 吡唑衍生物 | |
| JP3134097B2 (ja) | オキサゾール化合物 | |
| MX2008010004A (en) | Compounds and methods for modulating fx-receptors | |
| KR102406246B1 (ko) | Hsp90 억제제로서의 1,2,3-트리아졸 유도체 화합물 및 이의 용도 | |
| HK1110580B (en) | Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |